New concepts in predicting, evaluating, and managing neurodevelopmental outcomes in children with congenital heart

Bradley S Marino1

  • 1Department of Pediatrics, Division of Cardiology, Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Insights

Advances in congenital heart disease (CHD) care improve survival but increase neurodevelopmental deficits. Recent studies identify new predictors and interventions for better outcomes in children with CHD.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Surgery
  • Neurodevelopmental Science

Background:

  • Improved survival rates for infants with critical congenital heart disease (CHD) due to advances in surgery, cardiology, and intensive care.
  • Survivors of CHD often face neurodevelopmental deficits, behavioral issues, and emotional problems, impacting their quality of life.

Purpose of the Study:

  • Review significant and innovative studies from the past 18 months on predicting, evaluating, and managing neurodevelopmental outcomes in children with CHD.
  • Highlight new findings and interventions to improve the quality of life for high-risk CHD survivors.

Main Methods:

  • Review of recent scientific literature focusing on neurodevelopmental outcomes in pediatric CHD.
  • Analysis of new predictors, stratification schemata, and evidence-based guidelines.

Main Results:

  • Identification of novel predictors for adverse neurodevelopmental outcomes, including fetal cerebrovascular resistance, brain biomarkers, and perioperative electroencephalogram (EEG) abnormalities.
  • Inclusion of a new scientific statement from the American Heart Association (AHA) and American Academy of Pediatrics (AAP) on evaluating and managing neurodevelopmental outcomes.
  • Emergence of novel interventions aimed at improving neurodevelopmental outcomes.

Conclusions:

  • New intervention opportunities exist for improving fetal, perioperative, and long-term neurodevelopmental outcomes in CHD patients.
  • Updated AHA/AAP guidelines provide a framework for identifying and treating neurodevelopmental deficits in a significant population of CHD survivors.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.